Investors who purchased ImmunityBio Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026 are now defendants in a new securities class action lawsuit. The Rosen Law Firm filed the case on behalf of affected shareholders, and multiple additional law firms—including Robbins Geller Rudman & Dowd LLP, Pomerantz LLP, Robbins LLP, Kaplan Fox, and Bragar Eagel & Squire P.C.—have since launched parallel investigations.
If you purchased ImmunityBio stock during this window and experienced losses, you may be entitled to recover damages through the class action. The lawsuit stems directly from an FDA warning letter issued on March 24, 2026, in which federal regulators rejected ImmunityBio’s promotional claims that its bladder cancer treatment Anktiva “can cure and even prevent all cancer.” The company’s stock immediately cratered, falling $1.98 per share—a 21 percent decline—to close at $7.42 that same day. Shareholders are now alleging that company leadership made materially false statements about Anktiva’s capabilities and the company’s business prospects, deceiving investors about the true status of their flagship product. This article explains what happened, who is affected, critical deadlines you need to know, and what options are available to injured investors.
Table of Contents
- What Triggered the ImmunityBio Securities Class Action?
- Understanding the Allegations Against ImmunityBio
- Impact on Shareholders and Stock Performance
- Who Can Join the Class Action and How
- Important Deadlines and Critical Timelines
- Selecting Legal Representation and Firm Considerations
- What Comes Next and the Litigation Outlook
What Triggered the ImmunityBio Securities Class Action?
The central event that triggered the class action was the FDA’s March 24, 2026 warning letter to ImmunityBio regarding its marketing of Anktiva. Federal regulators found that the company had been making promotional claims that crossed critical regulatory lines—specifically, asserting that the treatment “can cure and even prevent all cancer.” These statements were not qualified, not supported by the evidence, and violated FDA rules governing how cancer drugs must be described to the public and to healthcare providers. The warning letter represented an official regulatory rebuke that immediately signaled to investors that ImmunityBio’s most closely watched product faced serious problems. The stock market reaction was severe and immediate.
On the day the FDA warning became public, IBRX shares dropped $1.98 per share, representing a 21 percent loss in market value. The stock closed at $7.42 per share. For investors who had bought in at higher prices during the January 19 to March 24 window—when the company was still making these disputed claims without public FDA correction—the losses were substantial. A shareholder who purchased 1,000 shares at an average price of $9.00 per share would have seen their position decline by approximately $1,980 in a single trading day. That kind of sudden, steep loss is exactly what triggers securities class actions.
Understanding the Allegations Against ImmunityBio
The class action lawsuit alleges that ImmunityBio and its leadership materially overstated the capabilities of Anktiva and made false statements about the company’s overall business, operations, and future prospects. In legal terms, “material misstatement” means the false information was significant enough that a reasonable investor would have considered it in making the investment decision. If Anktiva’s efficacy claims were as strong as the company suggested, then the company’s future revenue potential and profitability would be far greater. If those claims were overstated—as the FDA letter suggests—then the company’s prospects were fundamentally weaker than investors believed. The FDA warning letter is the key evidence supporting the claim that statements were false.
Regulatory agencies don’t issue warning letters casually. The fact that the FDA took the step of formally documenting problematic promotional claims creates a paper trail showing that ImmunityBio’s marketing of Anktiva was not merely aggressive or optimistic—it crossed into territory that federal regulators considered misleading and non-compliant. However, an FDA warning letter does not itself constitute a finding that investors were defrauded. That determination comes through the legal process. The warning letter provides evidence of what the company was saying and how regulators judged those statements, but the ultimate question of whether leadership knowingly misled investors—rather than simply made overly optimistic claims—remains to be litigated.
Impact on Shareholders and Stock Performance
The stock price decline on March 24, 2026 represents the most visible measure of investor harm. IBRX fell from a higher price point to $7.42 in a single day, a 21 percent collapse triggered by the FDA warning. However, the actual harm to shareholders extends beyond that one-day drop. Investors who held the stock through earlier periods during the January 19 to March 24 window were exposed to the full price range during this period—from whatever price they paid, down to the March 24 close.
Some shareholders may have purchased near the high point of the window, making their losses even more severe. For example, an investor who purchased 500 shares at $9.40 per share on February 15, 2026 (a hypothetical price near the middle of the class period) would have paid $4,700 total. That same position on March 24 would be worth approximately $3,710—a loss of $990 on a single investment, or about 21 percent. If that investor had held a larger position—say, $50,000 in stock—the one-day loss would exceed $10,000. These are not theoretical numbers; they represent real losses experienced by real people whose retirement accounts, investment portfolios, or trading positions took direct hits when the FDA warning became public.
Who Can Join the Class Action and How
The class action covers investors who purchased ImmunityBio securities during the period from January 19, 2026 through March 24, 2026. This includes anyone who bought IBRX stock during this window, whether through a brokerage account, retirement account, or any other investment vehicle. If you fit this description and experienced a loss, you likely have a claim. Joining the class action is straightforward, though it does require action on your part.
You will need to file a claim with the claims administrator once the settlement process moves forward, or you may participate early by seeking an appointment as lead plaintiff. The deadline to seek lead plaintiff appointment is May 26, 2026—this is a critical date that you should mark on your calendar. Lead plaintiffs are shareholders who have suffered substantial losses and are willing to serve as representatives in the case on behalf of all other class members. Being a lead plaintiff involves some additional responsibility and potential court appearances, but it also gives you greater say in how the case is managed. If you are not interested in serving as lead plaintiff, you can still recover through the class action once a settlement is reached; you simply need to file a claim form and provide documentation of your purchase and sale.
Important Deadlines and Critical Timelines
The lead plaintiff appointment deadline of May 26, 2026 is the single most important date for investors to understand. If you wish to serve as the representative for the class, you must act before this date. This deadline is strictly enforced by federal courts; if you miss it, you can still participate in the class action, but you lose the opportunity to have direct input into settlement negotiations and case strategy. That said, if you are primarily interested in recovering losses rather than serving in a leadership capacity, missing the lead plaintiff deadline does not prevent you from eventually collecting a settlement payment. The broader class action timeline typically extends over 12 to 24 months from filing.
The case has been brought by experienced securities litigation firms, which suggests a methodical approach rather than a rush. Defendants will file motions to dismiss, which courts will evaluate. If the case survives early motions, discovery will proceed—this is when attorneys for both sides exchange documents, conduct depositions, and build evidence. A settlement is typically reached well before trial, though there is always the possibility of going to trial if the parties cannot reach agreement. The key point for shareholders is that this process takes time, but once resolved, claim forms will be distributed to all eligible investors.
Selecting Legal Representation and Firm Considerations
Multiple law firms have taken on the ImmunityBio matter, including Rosen Law Firm (which filed first), Robbins Geller Rudman & Dowd LLP, Pomerantz LLP, Robbins LLP, Kaplan Fox, and Bragar Eagel & Squire P.C. If you want to join as lead plaintiff or if you simply want individual legal representation, you should understand that many of these firms work on a contingency basis—meaning they only collect payment if they recover money for investors. There are no upfront costs to join. When choosing representation, consider the firm’s track record in similar securities cases.
Robbins Geller and other firms on this list have substantial histories with successful securities litigation recoveries. Ask potential counsel about their experience specifically in FDA warning letter cases or pharmaceutical company securities suits, as these tend to have particular nuances. It’s also worth noting that you do not have to hire an attorney to recover as a class member; once the settlement is finalized, you can file a claim on your own by submitting documentation of your purchase and sale. However, having counsel review your claim to ensure it’s filled out correctly can be valuable.
What Comes Next and the Litigation Outlook
The ImmunityBio case follows a well-established path in securities litigation. Early indicators suggest multiple law firms view this as a viable case—the swift filing and parallel investigations are typical when there is strong factual support (in this instance, the FDA warning letter). The timeline from here involves the defendants responding to the complaint, motions practice, and eventually settlement discussions or discovery depending on how the case develops.
One factor that may influence the case’s progression is whether the FDA warning letter leads to broader regulatory action against ImmunityBio or its executives. If the FDA escalates—for instance, by seeking criminal referrals or proposing significant restrictions on the company—that would add pressure for settlement. Conversely, if the company can demonstrate that the promotional language was isolated to specific marketing materials and not reflective of broader intent to mislead, that could complicate plaintiff’s arguments. For now, shareholders should focus on preserving documentation of their purchases and losses and meeting the May 26, 2026 lead plaintiff deadline if they wish to participate actively.